Dosing regimen for Janus Kinase (JAK) inhibitors
US9522151B2 · kind B2 · utility
2Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 2013 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | Jul 18, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for treating allergic dermatitis, atopic dermatitis, or one or more symptoms thereof in a mammal in need, which method comprises administering to the mammal a first therapeutically effective dose of a Janus Kinase (JAK) inhibitor twice a day for a number of days sufficient to ease or eliminate one or more clinical signs in the mammal, followed by a second therapeutically effective dose of the JAK inhibitor at a reduced frequency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.